JPWO2021193928A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021193928A5 JPWO2021193928A5 JP2022510744A JP2022510744A JPWO2021193928A5 JP WO2021193928 A5 JPWO2021193928 A5 JP WO2021193928A5 JP 2022510744 A JP2022510744 A JP 2022510744A JP 2022510744 A JP2022510744 A JP 2022510744A JP WO2021193928 A5 JPWO2021193928 A5 JP WO2021193928A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor cells
- cancer
- sodium
- verteporfin
- talaporfin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004881 tumor cell Anatomy 0.000 claims 19
- VSEIDZLLWQQJGK-CHOZPQDDSA-N CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O Chemical compound CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O VSEIDZLLWQQJGK-CHOZPQDDSA-N 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 229950010924 talaporfin Drugs 0.000 claims 10
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 claims 8
- 229960004293 porfimer sodium Drugs 0.000 claims 8
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 claims 8
- 229960003895 verteporfin Drugs 0.000 claims 8
- 101710112752 Cytotoxin Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims 4
- 239000002619 cytotoxin Substances 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 239000013076 target substance Substances 0.000 claims 4
- 108010084592 Saporins Proteins 0.000 claims 3
- 102100024152 Cadherin-17 Human genes 0.000 claims 2
- 101710196881 Cadherin-17 Proteins 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 2
- 101710116743 Ephrin type-A receptor 2 Proteins 0.000 claims 2
- 102000010956 Glypican Human genes 0.000 claims 2
- 108050001154 Glypican Proteins 0.000 claims 2
- 108050007237 Glypican-3 Proteins 0.000 claims 2
- 230000001678 irradiating effect Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 claims 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 101150097792 Robo1 gene Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000012991 uterine carcinoma Diseases 0.000 claims 1
Claims (13)
- 腫瘍細胞表面の標的物質に結合する物質と細胞毒との結合物；及び
タラポルフィンナトリウム、ポルフィマーナトリウムまたはベルテポルフィン；
を含む、腫瘍細胞を死滅させるための医薬。 - 腫瘍細胞表面の標的物質に結合する物質が、抗体、抗体断片、リガンド、又はペプチドである請求項１に記載の医薬。
- 細胞毒が サポリン、ゲロニン、または緑膿菌外毒素である、請求項１又は２に記載の医薬。
- 腫瘍細胞が、細胞表面にＥｐｉｄｅｒｍａｌ Ｇｒｏｗｔｈ Ｆａｃｔｏｒ Ｒｅｃｅｐｔｏｒ（ＥＧＦＲ、ＥＲＢＢ１，ＥＲＢＢ２，ＥＲＢＢ３，ＥＲＢＢ４），Ｍｅｓｏｔｈｅｌｉｎ，Ｅｐｈｒｉｎ ｔｙｐｅ－Ａ ｒｅｃｅｐｔｏｒ ２（ＥｐｈＡ２），Ｇｌｙｐｉｃａｎ３（ＧＰＣ３），Ｃａｄｈｅｒｉｎ１７（ＣＤＨ１７）、又はＲｏｕｎｄａｂｏｕｔ ｈｏｍｏｌｏｇ １（Ｒｏｂｏ１）を発現している細胞である、請求項１から３の何れか一項に記載の医薬。
- 腫瘍細胞が、頭頚部がん、肺がん，肝がん、大腸がん、皮膚がん、食道がん、胃がん、子宮けいがん、子宮内膜がん、中皮腫、脳腫瘍、悪性黒色腫、乳がん、胆管がん、膵がん、卵巣がん、腎がん、膀胱がん、前立腺がん又は悪性リンパ腫、骨肉腫の何れかのがん細胞である、請求項１から４の何れか一項に記載の医薬。
- （１）前記結合物を腫瘍細胞と接触させる工程；
（２）タラポルフィンナトリウム、ポルフィマーナトリウムまたはベルテポルフィンを前記腫瘍細胞と接触させる工程；及び
（３）タラポルフィンナトリウム、ポルフィマーナトリウムまたはベルテポルフィンを活性化させるのに有効な波長で前記腫瘍細胞を照射することにより前記細胞を死滅させる工程：
により腫瘍細胞を死滅させる、請求項１から５の何れか一項に記載の医薬。 - （１）タラポルフィンナトリウム、ポルフィマーナトリウムまたはベルテポルフィンを腫瘍細胞と接触させる工程；
（２）前記結合物を前記腫瘍細胞と接触させる工程；及び
（３）タラポルフィンナトリウム、ポルフィマーナトリウムまたはベルテポルフィンを活性化させるのに有効な波長で前記腫瘍細胞を照射することにより前記細胞を死滅させる工程：
により腫瘍細胞を死滅させる、請求項１から５の何れか一項に記載の医薬。 - （１）前記結合物と、タラポルフィンナトリウム、ポルフィマーナトリウムまたはベルテポルフィンとを腫瘍細胞と接触させる工程、及び
（２）その後、タラポルフィンナトリウム、ポルフィマーナトリウムまたはベルテポルフィンを活性化させるのに有効な波長で前記腫瘍細胞を照射することにより前記細胞を死滅させる工程：
により腫瘍細胞を死滅させる、請求項１から５の何れか一項に記載の医薬。 - タラポルフィンナトリウム、ポルフィマーナトリウムまたはベルテポルフィンを活性化させるのに有効な波長が６５０ｎｍである、請求項６～８の何れか一項に記載の医薬。
- 腫瘍細胞表面の標的物質に結合する物質が抗ＥＧＦＲ抗体であり、細胞毒がサポリンであり、タラポルフィンナトリウムを含む、請求項１から９の何れか一項に記載の医薬。
- 抗ＥＧＦＲ抗体がＣｅｔｕｘｉｍａｂである、請求項１０に記載の医薬。
- 腫瘍細胞表面の標的物質に結合する物質が抗ＨＥＲ２抗体であり、細胞毒がサポリンであり、タラポルフィンナトリウムを含む、請求項１から９の何れか一項に記載の医薬。
- 抗ＨＥＲ２抗体がＴｒａｓｔｕｚｕｍａｂである、請求項１２に記載の医薬。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020057561 | 2020-03-27 | ||
| JP2020057561 | 2020-03-27 | ||
| PCT/JP2021/012922 WO2021193928A1 (ja) | 2020-03-27 | 2021-03-26 | 腫瘍細胞を死滅させるための医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021193928A1 JPWO2021193928A1 (ja) | 2021-09-30 |
| JPWO2021193928A5 true JPWO2021193928A5 (ja) | 2023-01-24 |
| JP7329288B2 JP7329288B2 (ja) | 2023-08-18 |
Family
ID=77891937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022510744A Active JP7329288B2 (ja) | 2020-03-27 | 2021-03-26 | 腫瘍細胞を死滅させるための医薬 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230135752A1 (ja) |
| EP (1) | EP4129333A1 (ja) |
| JP (1) | JP7329288B2 (ja) |
| CN (1) | CN115335082A (ja) |
| WO (1) | WO2021193928A1 (ja) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Tech | Methoden zur Herstellung humanisierter Antikörper |
| PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス，インク． | 異種抗体の生産 |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
| WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1694840A2 (en) * | 2003-12-19 | 2006-08-30 | Antisense Pharma GmbH | Combination therapy associating a tgf-beta antagonist with a chemotherapeutic agent |
| WO2006084078A2 (en) * | 2005-02-02 | 2006-08-10 | Raven Biotechnologies, Inc. | Jam-3 and antibodies that bind thereto |
| DOP2006000277A (es) * | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| DE102005062440B4 (de) * | 2005-12-27 | 2011-02-24 | Lts Lohmann Therapie-Systeme Ag | Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen |
| JP5514482B2 (ja) * | 2009-07-15 | 2014-06-04 | 株式会社荏原製作所 | 給水装置及び給水システム |
| CN110229323B (zh) * | 2019-05-31 | 2022-02-25 | 苏州大学 | 还原敏感可逆交联的具有不对称膜结构的聚合物囊泡及其在制备治疗肝癌药物中的应用 |
-
2021
- 2021-03-26 WO PCT/JP2021/012922 patent/WO2021193928A1/ja active Application Filing
- 2021-03-26 CN CN202180024823.6A patent/CN115335082A/zh active Pending
- 2021-03-26 JP JP2022510744A patent/JP7329288B2/ja active Active
- 2021-03-26 EP EP21776170.9A patent/EP4129333A1/en active Pending
- 2021-03-26 US US17/913,578 patent/US20230135752A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mironova et al. | Genetically encoded immunophotosensitizer 4D5scFv-miniSOG is a highly selective agent for targeted photokilling of tumor cells in vitro | |
| Carpin et al. | Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells | |
| Boku | HER2-positive gastric cancer | |
| Neve et al. | The role of overexpressed HER2 in transformation | |
| Zhu et al. | Multifunctional receptor-targeting antibodies for cancer therapy | |
| JP2020506971A5 (ja) | ||
| JP2022153392A5 (ja) | ||
| Moradi-Kalbolandi et al. | Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER | |
| Stangl et al. | Detection of irradiation-induced, membrane heat shock protein 70 (Hsp70) in mouse tumors using Hsp70 Fab fragment | |
| Pomerantz et al. | The role of epidermal growth factor receptor in head and neck squamous cell carcinoma | |
| Oraki Kohshour et al. | Ablation of breast cancer cells using trastuzumab‐functionalized multi‐walled carbon nanotubes and trastuzumab‐diphtheria toxin conjugate | |
| Glynne-Jones et al. | The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers | |
| JPWO2021193928A5 (ja) | ||
| Vempati et al. | Phase I trial of dose-escalated stereotactic radiosurgery (SRS) boost for unfavorable locally advanced oropharyngeal cancer | |
| Wilkins et al. | Development of antibodies for cancer therapy | |
| Williams | H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich honored with the 2019 Lasker~ DeBakey Clinical Medical Research Award | |
| AU2022386318A1 (en) | Combination cancer therapy with memory nk cells and anti-cancer bispecific molecules | |
| Atwell et al. | Nuclear epidermal growth factor receptor as a therapeutic target | |
| JP7329288B2 (ja) | 腫瘍細胞を死滅させるための医薬 | |
| Zhu et al. | Targeting HER2 in advanced breast cancer | |
| Farhadihosseinabadi et al. | Breast cancer: risk factors, diagnosis and management | |
| Lan et al. | Novel immunotherapies for breast cancer: Focus on 2023 findings | |
| Lacuzzo et al. | HER2-Low Breast Cancer: Prognosis and Future Treatment Prospective | |
| Khirehgesh et al. | Design and construction a novel humanized biparatopic nanobody-based immunotoxin against epidermal growth factor receptor (EGFR) | |
| Gockel et al. | Novel therapeutic targets in esophageal cancer: impact of chemokine receptor CXCR4 |